about
Targeted Radionuclide Therapy of Human TumorsDysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsCirculating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic CancerAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Pepsin-Containing Membranes for Controlled Monoclonal Antibody Digestion Prior to Mass Spectrometry Analysis.Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapyImmunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.A Strategy for Screening Monoclonal Antibodies for Arabidopsis FlowersCancer immunotherapy: Strategies for personalization and combinatorial approaches.Research and development of therapeutic mAbs: An analysis based on pipeline projects.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.From rabbit antibody repertoires to rabbit monoclonal antibodiesSafety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Monoclonal antibodies: technologies for early discovery and engineering.Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.Combinatorial drug delivery approaches for immunomodulation.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.Use of polyclonal/monoclonal antibody therapies in transplantation.Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Emerging antibodies for the treatment of multiple myeloma.Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.Improved Targeting of Cancers with Nanotherapeutics.Delivering safer immunotherapies for cancer.Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1.Antisense oligonucleotide and thyroid hormone conjugates for obesity treatmentHER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosisNew platform for simple and rapid protein-based affinity reactions.A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles.
P2860
Q26771267-EFA8B443-863E-4D99-90F4-E04CE237FF57Q26771367-602EC0A8-40B1-4D5F-9CFD-289023F3D764Q28072319-DEF1EE5F-C4C3-4A87-9342-CB5438D7E9B8Q28073765-DDCEE599-CC2D-4657-94E1-512C67EE1C4AQ30275229-C7E58EEB-FC94-42F5-9019-2C1A0D0A4468Q30276243-4860F27A-D819-420B-92D0-996854F428C2Q30278544-1EFB4EFE-15C6-4B24-B9CD-E74DDE3BA9B9Q33779567-DC79BE3E-3F42-4703-B140-616E6FF667EFQ33781380-B34757D2-6DFB-43C6-96F8-93ADCB4CB178Q33838679-1F49A2B2-9909-4BBE-B82D-EBD683CD564BQ35975965-971926AE-0566-443C-AE97-52D47FF3252BQ36307988-6D6C86CE-90B5-461F-AAA1-F055FF124E52Q36387028-2757C058-D572-4513-8989-AE37CE527824Q37027607-318CA661-425F-4AA6-943D-A24C94A81432Q37114367-B47C6C36-0A76-4859-A14B-001CFE4EC6D7Q37367593-220D0795-F263-4540-832E-03ADBC718D1AQ37739483-1EC22A20-A76E-45B9-84F5-1998E4FBA2BBQ38633532-F30A4CBE-1CCD-409D-BB3D-2E64960E5A61Q38633596-4B485087-77EB-49A2-83C2-4B59597C7A9CQ38671390-02AE5D6E-0E94-4582-9CEA-26C351AB026DQ38680602-FE2B382D-FA5B-43B9-9A50-C4B36595EFBEQ38700209-F97EC475-1E66-4DC9-B1B3-0E50E5562419Q38708078-A0606338-E617-47E9-A537-650670A4124BQ38726039-8367FD81-8B72-4CEF-ADCF-807622078D01Q38728585-84D735C0-97F2-462C-BFA2-781746CDA348Q38730371-06D3A1B3-C17D-4A57-AF0B-680B1F4C960AQ38769922-4B7A0BB5-2E89-4443-914E-7C813A724B1DQ38782706-DB8A4F20-5939-4ECB-9D55-83619D0E80F3Q38838239-C068F1A8-ADFF-472C-9764-F08825A9EFD2Q38903356-C464DA9F-6193-4CF4-AB18-89F9733EBBB1Q38969858-4ED5C971-62A9-423A-8F6E-CC4A3C64BADDQ39014899-B7D8A30B-ABE0-4AC0-8C89-FA74DA252CA3Q39114835-222B14C5-6465-4CA1-AB90-A3768332A0A3Q39330984-B50DEDBC-E30A-4078-A18D-D6995BD24BEDQ40077073-849F25FF-8843-460D-998E-2BDE90F5B904Q41242816-D3B5D5B9-5FF9-486F-AFBC-E5C0569355B8Q41517624-55140AB0-F014-492B-8B1D-05DEBBC8BDDEQ41909130-2A2C5966-36F5-4399-AEC6-6806FED96F58Q41960548-F7CEB2B7-89E7-4963-BBB6-49CF7F4113E2Q42198535-155CEF44-2298-47B4-B031-5372D572474B
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Building better monoclonal antibody-based therapeutics.
@ast
Building better monoclonal antibody-based therapeutics.
@en
type
label
Building better monoclonal antibody-based therapeutics.
@ast
Building better monoclonal antibody-based therapeutics.
@en
prefLabel
Building better monoclonal antibody-based therapeutics.
@ast
Building better monoclonal antibody-based therapeutics.
@en
P2860
P356
P1476
Building better monoclonal antibody-based therapeutics
@en
P2093
George J Weiner
P2860
P2888
P304
P356
10.1038/NRC3930
P407
P577
2015-06-01T00:00:00Z